Thus, targeting of this novel ErbB2/EGFR-ERK1/2/ROCK pathway in diabetes-induced vascular complications might be clinically useful especially when there is already a vast experience with the use of ErbB2 inhibitors in several cancers [10], [30]. This evidence concerns the gene MAPK3 and diabetes mellitus.